Overview
Shifting the Focus: Endocrinology-Led Practices for Complication-Centric Management of T2D Through Optimization of GLP-1 RAs and Dual GIP/GLP-1 RAs
Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.
Start Activity
Type 2 diabetes (T2D) is a major cause of morbidity and mortality that is highly associated with the comorbidities of ASCVD, CKD, and obesity, among others. Despite guideline recommendations, antihyperglycemic agents with cardioprotective benefits continue to be underutilized in patients for whom these therapies are clearly indicated. This can be attributed in part to the complexity of patients coupled with a vast amount of outcomes data, leading to a more complicated decision-making process and persistent clinical inertia.
To support endocrinology providers in their ability to navigate this complexity, this training program, modeled on the CDC Training of Trainers approach, provides learners with the tools and resources to individualize therapeutic targets and glucose-lowering regimens based on multiple factors, including the presence of comorbidities, such as obesity or cardiovascular risk.
Learners who complete the training can download expert-developed educational content and practical tools to facilitate peer-to-peer learning with their clinical team and enhance their routine practices for complication-centric management of T2D.
This activity is intended for endocrinologists, endocrinology NPs/PAs, and other members of the multidisciplinary care team.
The comorbidities associated with T2D (ie, cardiovascular disease and obesity) contribute to its significant morbidity and mortality. Accumulating data from CVOTs have demonstrated the benefits of GLP-1 RAs, not just for glycemic management, but for improving outcomes related to MACEs in those with T2D. Clinical practice guidelines consistently recommend GLP-1 RAs and dual GIP/GLP-1 RAs based on their glycemic and nonglycemic effects, and new safety and efficacy data continually advance our understanding of the role of these therapies for patients with T2D. However, clinicians remain challenged to implement GLP-1 RA and dual GIP/GLP-1 RA therapy in clinical practice for patients with T2D, including those with comorbidities who would benefit from the nonglycemic effects of these therapies. This activity will assist clinicians with effective translation of the latest guideline recommendations and clinical trial data into real-world practice.
Upon completion of this activity, learners will be able to:
• Describe the benefits of earlier treatment intensification and weight loss in achieving glycemic goals and reducing the risk of CVD in patients with T2D
• Describe the latest research on the role of GLP-1 RAs and dual GIP/GLP-1 RAs in treating hyperglycemia and long-term complications of T2D
• Incorporate strategies to improve earlier risk recognition, screening, and diagnosis of microvascular and macrovascular complications in patients with T2D
• Develop complication-centric treatment plans considerate of patient preferences and individualized therapeutic targets for at-risk T2D patients
• Describe the benefits of earlier treatment intensification and weight loss in achieving glycemic goals and reducing the risk of CVD in patients with T2D
• Describe the latest research on the role of GLP-1 RAs and dual GIP/GLP-1 RAs in treating hyperglycemia and long-term complications of T2D
• Incorporate strategies to improve earlier risk recognition, screening, and diagnosis of microvascular and macrovascular complications in patients with T2D
• Develop complication-centric treatment plans considerate of patient preferences and individualized therapeutic targets for at-risk T2D patients
Provided by the Academy for Continued Healthcare Learning (ACHL).
This activity is supported by an educational grant from Lilly
Lee-Shing Chang, MD
Instructor, Department of Medicine
Harvard Medical School
Associate Physician, Department of Medicine, Division of Endocrinology, Diabetes, and Hypertension
Brigham and Women’s Hospital
Boston, MA
Instructor, Department of Medicine
Harvard Medical School
Associate Physician, Department of Medicine, Division of Endocrinology, Diabetes, and Hypertension
Brigham and Women’s Hospital
Boston, MA
Kathleen M. Dungan, MD, MPH
Professor of Medicine, Division of Endocrinology, Diabetes, & Metabolism
College of Medicine, The Ohio State University
The Ohio State University Wexner Medical Center
Columbus, OH
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with all ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Lee-Shing Chang, MD (Faculty)
Grants/Research Support: Amgen, Amylyx Pharmaceuticals, Applied Therapeutics, AstraZeneca, Better Therapeutics, Boehringer Ingelheim, Corcept Therapeutics, Eli Lilly, Fractyl Health, Novo Nordisk, Rhythm Therapeutics
Kathleen M. Dungan, MD, MPH (Faculty)
Consultant: Dexcom, Eli Lilly, Elsevier, Insulet, Oppenheimer
Grants/Research Support: Dexcom, Endogenex, Insulet, Novo Nordisk, Sequel Med Tech
Royalties: UptoDate
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Discussion of scientific information on unapproved uses (SIUU), off-label, investigational, or experimental drug/device use: investigational GLP-1 RA-based therapies, including oforglipron, retatrutide, efinopegdutide, survodutide, cagrilintide + semaglutide, amycretin, and maridebart cafraglutide
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Discussion of scientific information on unapproved uses (SIUU), off-label, investigational, or experimental drug/device use: investigational GLP-1 RA-based therapies, including oforglipron, retatrutide, efinopegdutide, survodutide, cagrilintide + semaglutide, amycretin, and maridebart cafraglutide
This activity will take approximately 3 hours to complete. To receive credit, learners are required to complete the pre-assessment, view the online activity, and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
